Suppr超能文献

非酒精性脂肪性肝病患者的死亡率和疾病进展的模式和预测因素。

Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.

机构信息

Department of Internal Medicine, Ruhr-University, Bochum, Germany.

Health Economics Outcomes Research, Gilead Sciences Inc., Foster City, CA, USA.

出版信息

Aliment Pharmacol Ther. 2020 Oct;52(7):1185-1194. doi: 10.1111/apt.16016. Epub 2020 Aug 17.

Abstract

BACKGROUND

Factors associated with mortality and disease progression in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are poorly understood.

AIMS

To assess the impact of liver disease severity, demographics and comorbidities on all-cause mortality and liver disease progression in a large, real-world cohort of NAFLD patients.

METHODS

Claims data from the German Institut für angewandte Gesundheitsforschung database between 2011 and 2016 were analyzed retrospectively. Adult patients diagnosed with NAFLD and/or NASH were categorised as NAFLD, NAFLD non-progressors, compensated cirrhosis, decompensated cirrhosis, liver transplant or hepatocellular carcinoma (HCC). The longitudinal probability of mortality and incidence of progression were calculated for disease severity cohorts and multivariable analyses performed for adjusted mortality.

RESULTS

Among 4 580 434 patients in the database, prevalence of NAFLD was 4.7% (n = 215 655). Of those, 36.8% were non-progressors, 0.2% compensated cirrhosis, 9.6% decompensated cirrhosis, 0.0005% liver transplant and 0.2% HCC. Comorbidity rates were significantly higher in compensated cirrhosis, decompensated cirrhosis and HCC compared with non-progressors. The longitudinal probability of mortality for non-progressors, compensated cirrhosis, decompensated cirrhosis and HCC was 3.6%, 18.7%, 28.8% and 68%, respectively. Independent predictors of mortality included cardiovascular disease, type 2 diabetes mellitus, hypertension, obesity and renal impairment. The cumulative incidence of progression in NAFLD and compensated cirrhosis patients was 10.7% and 16.7%, respectively, over 5 years of follow-up.

CONCLUSION

NAFLD patients were severely under-diagnosed and had a high probability of mortality that increased with disease progression. Early identification and effective management to halt or reverse fibrosis are essential to prevent progression.

摘要

背景

非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)患者的死亡和疾病进展相关因素尚未完全明确。

目的

评估在一个大型真实世界的 NAFLD 患者队列中,肝脏疾病严重程度、人口统计学和合并症对全因死亡率和肝脏疾病进展的影响。

方法

回顾性分析了 2011 年至 2016 年德国应用健康研究学会数据库中的索赔数据。将诊断为 NAFLD 和/或 NASH 的成年患者分为 NAFLD、NAFLD 非进展者、代偿性肝硬化、失代偿性肝硬化、肝移植或肝细胞癌(HCC)。计算疾病严重程度队列的死亡率和进展发生率,并进行多变量分析以调整死亡率。

结果

在数据库的 4580434 名患者中,NAFLD 的患病率为 4.7%(n=215655)。其中,36.8%为非进展者,0.2%为代偿性肝硬化,9.6%为失代偿性肝硬化,0.0005%为肝移植,0.2%为 HCC。与非进展者相比,代偿性肝硬化、失代偿性肝硬化和 HCC 的合并症发生率显著更高。非进展者、代偿性肝硬化、失代偿性肝硬化和 HCC 的死亡率纵向概率分别为 3.6%、18.7%、28.8%和 68%。死亡的独立预测因素包括心血管疾病、2 型糖尿病、高血压、肥胖和肾功能不全。NAFLD 和代偿性肝硬化患者在 5 年的随访中,疾病进展的累积发生率分别为 10.7%和 16.7%。

结论

NAFLD 患者的诊断严重不足,死亡率随着疾病进展而增加。早期识别和有效的管理以阻止或逆转纤维化对于防止疾病进展至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验